Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations

Standard of care therapies for autosomal dominant polycystic kidney disease (ADPKD) may limit morbidity and mortality due to disease-related complications, but they do not delay disease progression. Tolvaptan, a selective vasopressin V2 receptor antagonist, delays the increase in kidney volume (a su...

Descripción completa

Detalles Bibliográficos
Autores: Sans Atxer, Laia, Joly, Dominique
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2018
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/35807
Acceso en línea:http://hdl.handle.net/10230/35807
http://dx.doi.org/10.2147/IJNRD.S125942
Access Level:acceso abierto
Palabra clave:Ronyons -- Malalties -- Tractament
ADPKD treatment
Autosomal dominant polycystic kidney disease
Tolvaptan
id ES_6fb6c97f197f2e82784b03d7feefced7
oai_identifier_str oai:recercat.cat:10230/35807
network_acronym_str ES
network_name_str España
repository_id_str
spelling Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerationsSans Atxer, LaiaJoly, DominiqueRonyons -- Malalties -- TractamentADPKD treatmentAutosomal dominant polycystic kidney diseaseTolvaptanStandard of care therapies for autosomal dominant polycystic kidney disease (ADPKD) may limit morbidity and mortality due to disease-related complications, but they do not delay disease progression. Tolvaptan, a selective vasopressin V2 receptor antagonist, delays the increase in kidney volume (a surrogate marker for disease progression), slows the decline in renal function, and reduces pain in ADPKD patients with relatively preserved renal function. The most common adverse events of tolvaptan are linked to its aquaretic effect, and rare cases of idiosyncratic hepatitis were observed. Additional ongoing studies will determine whether the benefits are sustained over time, whether they can be observed in patients with advanced kidney disease, and whether they can be translated in terms of quality of life and cost/effectiveness parameters. Tolvaptan is currently approved in Europe and several countries throughout the world. In real-life conditions, selection of patients that would be good theoretical candidates to tolvaptan is a key but complex question. Eligibility criteria slightly differ from one country to another, and several models (based on conventional data, genetics, renal volume) were recently proposed to identify patients with evidence or risk of rapid disease progression. Eligible patients will ultimately make the decision to start tolvaptan, after complete information, consideration, and balancing of benefits, adverse events, and risks.Dove Medical Press201820182018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/35807http://dx.doi.org/10.2147/IJNRD.S125942reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésInternational Journal of Nephrology and Renovascular Disease. 2018 Jan 31;11:41-51Copyright © 2018 Sans-Atxer and Joly. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributedhttps://creativecommons.org/licenses/by-nc/3.0/info:eu-repo/semantics/openAccessoai:recercat.cat:10230/358072026-05-29T05:05:01Z
dc.title.none.fl_str_mv Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
title Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
spellingShingle Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
Sans Atxer, Laia
Ronyons -- Malalties -- Tractament
ADPKD treatment
Autosomal dominant polycystic kidney disease
Tolvaptan
title_short Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
title_full Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
title_fullStr Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
title_full_unstemmed Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
title_sort Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
dc.creator.none.fl_str_mv Sans Atxer, Laia
Joly, Dominique
author Sans Atxer, Laia
author_facet Sans Atxer, Laia
Joly, Dominique
author_role author
author2 Joly, Dominique
author2_role author
dc.subject.none.fl_str_mv Ronyons -- Malalties -- Tractament
ADPKD treatment
Autosomal dominant polycystic kidney disease
Tolvaptan
topic Ronyons -- Malalties -- Tractament
ADPKD treatment
Autosomal dominant polycystic kidney disease
Tolvaptan
description Standard of care therapies for autosomal dominant polycystic kidney disease (ADPKD) may limit morbidity and mortality due to disease-related complications, but they do not delay disease progression. Tolvaptan, a selective vasopressin V2 receptor antagonist, delays the increase in kidney volume (a surrogate marker for disease progression), slows the decline in renal function, and reduces pain in ADPKD patients with relatively preserved renal function. The most common adverse events of tolvaptan are linked to its aquaretic effect, and rare cases of idiosyncratic hepatitis were observed. Additional ongoing studies will determine whether the benefits are sustained over time, whether they can be observed in patients with advanced kidney disease, and whether they can be translated in terms of quality of life and cost/effectiveness parameters. Tolvaptan is currently approved in Europe and several countries throughout the world. In real-life conditions, selection of patients that would be good theoretical candidates to tolvaptan is a key but complex question. Eligibility criteria slightly differ from one country to another, and several models (based on conventional data, genetics, renal volume) were recently proposed to identify patients with evidence or risk of rapid disease progression. Eligible patients will ultimately make the decision to start tolvaptan, after complete information, consideration, and balancing of benefits, adverse events, and risks.
publishDate 2018
dc.date.none.fl_str_mv 2018
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/35807
http://dx.doi.org/10.2147/IJNRD.S125942
url http://hdl.handle.net/10230/35807
http://dx.doi.org/10.2147/IJNRD.S125942
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv International Journal of Nephrology and Renovascular Disease. 2018 Jan 31;11:41-51
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by-nc/3.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc/3.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Dove Medical Press
publisher.none.fl_str_mv Dove Medical Press
dc.source.none.fl_str_mv reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410528251609089
score 15,811543

Similares en LA Referencia